We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Comment and Response |

BRAF V600E Mutation and Papillary Thyroid Cancer

Alessia Ciarrocchi, PhD1; Silvio Cavuto, MSc2; Simonetta Piana, MD3
[+] Author Affiliations
1Laboratory of Molecular Biology, Arcispedale S Maria Nuova-IRCCS, Reggio Emilia, Italy
2Scientific Directorate, Arcispedale S Maria Nuova-IRCCS, Reggio Emilia, Italy
3Pathology Unit, Arcispedale S Maria Nuova-IRCCS, Reggio Emilia, Italy
JAMA. 2013;310(5):534. doi:10.1001/jama.2013.8589.
Text Size: A A A
Published online


To the Editor The study by Dr Xing and colleagues1 explored the association between the BRAF V600E mutation and mortality in patients with papillary thyroid cancer (PTC) in a large retrospective cohort of 1849 patients from 13 centers worldwide. The authors concluded that the BRAF mutation was significantly associated with cancer-related mortality.

However, this work actually demonstrates that the BRAF mutation is just a marker of aggressiveness and not a true prognostic factor because it was significantly associated with aggressive features and mortality in the bivariable analysis. When other clinical variables were entered in the analysis, the correlation disappeared. Therefore, the way the data were described and the conclusion may be misleading.


Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview




August 7, 2013
Mingzhao Xing, MD, PhD
1Division of Endocrinology and Metabolism, Johns Hopkins University School of Medicine, Baltimore, Maryland
JAMA. 2013;310(5):534-535. doi:10.1001/jama.2013.8598.
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.

See Also...
Related Collections